stockportfolio.pro
Stocks / CSTL vs CTMX
CSTL vs CTMX
Castle Biosciences, Inc. and CytomX Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Castle Biosciences, Inc. (CSTL) | CytomX Therapeutics, Inc. (CTMX) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $344.23M | $76.20M |
| Net income (latest FY) | $-24.16M | $-17.37M |
| Revenue growth (5y CAGR) | 40.6% | 2.2% |
| Net margin | -7.0% | -22.8% |
| Return on equity | -5.1% | -17.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CSTL — free Open CTMX — freeFrequently asked questions
Which is bigger, CSTL or CTMX?
CytomX Therapeutics, Inc. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, CSTL or CTMX?
Over the last five fiscal years, Castle Biosciences, Inc. grew revenue faster — 40.6%/yr versus 2.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.